Aurinia Pharmaceuticals Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Aurinia Pharmaceuticals Inc 's ROA in the second quarter of 2026?
Aurinia Pharmaceuticals Inc achieved a return on average assets (ROA) of 44.67 % in its second quarter of 2026, this is above AUPH's average return on assets of -10.24%.
Aurinia Pharmaceuticals Inc assets over the 12 months ending in its second quarter of 2026 are valued at $703 million

ROA fell compared to the first quarter of 2026, despite the net income growth of 8.9% from the first quarter of 2026.

However, within the Healthcare sector 23 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 77, from total ROA ranking in the first quarter of 2026 at 94.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	57.62 %	46.88 %	23.1 %	-39.64 %	-39.05 %
Y / Y Net Income Change	73.91 %	47.17 %	14651.15 %	119.87 %	2879.64 %
Net Income (TTM) in million	314	298	287	78	61
Return On Assets (TTM)	44.67 %	47.28 %	50.24 %	14.51 %	9.73 %
AUPH's Total Ranking	# 77	# 94	# 353	# 506	# 842
Total Assets (TTM) in million	792	742	752	528	503
Seq. Total Assets Change	6.83 %	-1.34 %	42.47 %	4.97 %	-0.45 %
Seq. Net Income Change	8.9 %	-83.7 %	568.11 %	46.66 %	-7.84 %

AUPH's 5 Years Annual ROA >> Back to AUPH Management Effectiveness >> Compare AUPH ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 13
Sector	# 24
Overall	# 78

Return On Assets Statistics
High	Average	Low
50.24 %	-10.24 %	-42.41 %
(Dec 31 2025)		(Dec 31 2021)

Financial Statements
Aurinia Pharmaceuticals Inc 's Assets	$ 792 million	AUPH's Balance sheet
Aurinia Pharmaceuticals Inc 's Income	$ 37 million	Quarterly AUPH's Income Statement
AUPH's Income by Division		See AUPH's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	48.24 %	-29.58 %	2.07 %	-12.92 %	133.92 %
Total Assets in million	905	611	867	849	975
Y / Y Net Income Change	4893.08 %	-	-	-	-
Net Income in million	287	6	-78	-108	-181
Annual Return On Assets	31.73 %	0.94 %	-9 %	-12.73 %	-18.55 %

AUPH's 5 Years Annual ROA >> Back to AUPH Management Effectiveness >> Compare AUPH ROA to its Competitors

Comment on AUPH's ROA in the fiscal year ending 2025

In the fiscal year 2025 ROA improved to 31.73 % compared to prior year, due to annual net income growth of 4893.08 % to $287.20 million, while value of Aurinia Pharmaceuticals Inc 's overall assets grew just by 48.24 % to $905.09 million, compared to $905.09 a year before.

More Return On Assets Ratios
AUPH's' Return on Assets at Yahoo Finance
Major Pharmaceutical Preparations Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
AUPH's Roa Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for AUPH's Competitors
Subscribers only: Roa for Aurinia Pharmaceuticals Inc 's Suppliers
Subscribers only: Return On Assets for AUPH's Customers

You may also want to know
AUPH's Roi	AUPH's Inventory Turnover Ratio	AUPH's Growth Rates	AUPH's Dividend Comparisons
	AUPH's Profitability Ratios	AUPH's Asset Turnover Ratio	AUPH's Dividend Growth
AUPH's Roe	AUPH's Valuation Ratios	AUPH's Financial Strength Ratios	AUPH's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector	ROA
Elutia Inc	108.72 %
Silexion Therapeutics Corp	99.09 %
Arbutus Biopharma Corp	96.04 %
Pulmatrix Inc	94.81 %
Quince Therapeutics Inc	88.46 %
Interpace Biosciences Inc	85.91 %
Oncotelic Therapeutics Inc	81.75 %
Rigel Pharmaceuticals Inc	72.27 %
Actinium Pharmaceuticals Inc	71.73 %
Sanuwave Health Inc	71.60 %
Exelixis Inc	70.51 %
Rallybio Corporation	64.51 %
Oramed Pharmaceuticals Inc	64.18 %
Fortress Biotech Inc	60.88 %
Atlantic Coastal Acquisition Corp Ii	54.09 %
Lensar Inc	47.48 %
Elite Pharmaceuticals Inc	46.11 %
Omeros Corporation	46.05 %
Q32 Bio Inc	45.18 %
Aurinia Pharmaceuticals Inc	44.95 %
Agenus Inc	44.86 %
Earth Science Tech Inc	44.02 %
Liquidia Corporation	36.30 %
Ironwood Pharmaceuticals inc	34.34 %
Idexx Laboratories Inc	33.61 %
Tg Therapeutics Inc	33.59 %
Meiragtx Holdings Plc	29.37 %
Indivior Pharmaceuticals Inc	28.21 %
Qhslab Inc	27.12 %
Adma Biologics Inc	26.58 %

Date modified: 2026-09-26T07:37:49+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.